Nampt Inhibition Uncovers Therapeutic Vulnerabilities to Venetoclax and Chemotherapy in Acute Myelogenous Leukemia

Authors

John R Sanchez
Chaomei Liu
Vishakha Pawar
Yanqing Huang
Daisy Diaz-Rohena
Jyotsana Singh
Priya Koppikar
Tzung-Huei Lai
Lisa St John
Vinay Puduvalli
Jeffrey Molldrem
Palaniraja Thandapani
Nitin Jain
Rosa Lapalombella
Deepa Sampath

Language

English

Publication Date

1-1-2026

Journal

Leukemia & Lymphoma

DOI

10.1080/10428194.2025.2571199

PMID

41401031

Abstract

Acute myeloid leukemia (AML) cells depend on nicotinamide adenine dinucleotide (NAD

Keywords

Humans, Nicotinamide Phosphoribosyltransferase, Leukemia, Myeloid, Acute, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Cytokines, Antineoplastic Combined Chemotherapy Protocols, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Acrylamides, Cell Line, Tumor, Drug Synergism, Piperidines, AML, BCL-2 dependency, DNA repair impairment, KPT-9274, NAMPT inhibition, metabolic vulnerability

Published Open-Access

yes

Recommended Citation

Sanchez, John R; Liu, Chaomei; Pawar, Vishakha; et al., "Nampt Inhibition Uncovers Therapeutic Vulnerabilities to Venetoclax and Chemotherapy in Acute Myelogenous Leukemia" (2026). Faculty, Staff and Student Publications. 6294.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/6294